(EVGN) Evogene Ltd. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVGN) Evogene Ltd. Complete Analysis Pack
Your Credibility Toolkit Starts Here
This Evogene Ltd. SWOT Analysis gives a concise, structured view of the company’s strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; this page includes a real preview/sample so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use analysis.
Strengths
3 core divisions
Evogene Ltd. runs 3 core divisions: Agriculture, Human Health, and Industrial Applications. That setup spreads innovation across 3 life-science markets, so one weak end market does not define the whole business. It also helps reduce dependence on any single revenue stream, which can support steadier growth.
CPB AI platform
Evogene Ltd.’s proprietary CPB (Computational Predictive Biology) platform is its core technology engine, combining deep biology, big data analytics, and AI to guide discovery. It can improve target selection and cut trial-and-error in R&D, which matters for a company that reported 2025 revenue of $0.0 million from product sales and continues to rely on platform-led value creation. This gives Evogene Ltd. a scalable edge in finding better hits faster.
1999 founding
Evogene was founded in 1999, giving it about 25 years of operating history by 2025/2026. That long run has helped build scientific know-how and partnering experience, which matters in crop biology and seed tech. A 25-year track record can also make Evogene more credible with large industry collaborators.
US Israel Brazil presence
Evogene Ltd. has operations in the United States, Israel, Brazil, and other markets, which widens its access to R&D talent, customers, and crop systems. This multi-region base also helps it commercialize across farm climates and regulatory settings, lowering reliance on one market. In FY2025, that geographic spread supported broader partner reach and faster field validation.
- US, Israel, Brazil footprint
- Better talent and customer access
- Fits multi-region commercialization
BASF Corteva Bayer ties
Evogene's ties with BASF, Corteva, and Bayer give it validation from 3 global crop-input leaders. These links can support funding, speed development, and lift adoption odds because big partners usually back tech only after technical review and commercial fit.
- 3 top-tier partners
- Market validation signal
- Can aid funding and adoption
Evogene’s AI Engine and Global Partners Drive Its Core Strengths
Evogene Ltd.’s strengths are its CPB AI-driven discovery engine, which supports faster target selection, its 3-division setup across Agriculture, Human Health, and Industrial Applications, and its long operating history since 1999. Its U.S.-Israel-Brazil footprint and 3 global partners BASF, Corteva, and Bayer add reach and validation, while FY2025 product sales stayed at $0.0 million.
| Strength | Data point |
|---|---|
| Operating history | Founded 1999 |
| Partner validation | BASF, Corteva, Bayer |
| Revenue base | 2025 product sales: $0.0 million |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Evogene Ltd.’s business strategy
Editable Excel File
Gives a quick, structured SWOT snapshot for Evogene Ltd. to simplify strategic decisions.
Reference Sources
Lists primary, reputable sources for Evogene to speed due diligence and let stakeholders verify key claims quickly.
Weaknesses
Early-stage pipeline
Evogene's model is discovery-led, so much of its pipeline is still pre-commercial. That creates high technical and execution risk: in drug development, only about 1 in 10 candidates reaches approval. With limited mature product sales, 2025/2026 results still depend on turning early programs into funded milestones.
3-sector complexity
Evogene Ltd. runs three very different tracks: Agriculture, Human Health, and Industrial Applications. That 3-sector spread raises execution risk, because each line needs its own science, sales, and funding focus. With one management team and limited capital, focus can slip and spending can get thin across all 3 markets.
Partner dependence
Evogene’s partner model is a real weakness because large partners are often the gatekeepers for validation and commercialization. That leaves the Company exposed to outside timelines, budget shifts, and go-to-market choices, so even one delayed partner decision can slow the pipeline. In 2025, this matters more because small biotech platform firms like Evogene still need external funding and execution support to move projects from research into revenue.
Specialized technology risk
Evogene Ltd.’s weakness is its heavy dependence on the CPB platform: if CPB’s predictive results do not keep turning into real products, the value case weakens fast. Platform-led biotech models are exposed to scientific setbacks, and one miss can affect the whole story. In 2025, that concentration risk still mattered because the company’s platform remained the core of its business model.
- CPB drives most of the value story.
- Weak product conversion hurts credibility.
- Scientific misses can hit the whole model.
Medical cannabis exposure
Evogene Ltd.'s medical cannabis exposure comes through a subsidiary, so it adds another layer of regulation, licensing, and operating risk. This side business can be harder to scale than core discovery work, and it can pull cash and management time away from higher-value R&D. That matters when the main growth case depends on platform programs, not cannabis sales.
- Extra regulatory and compliance burden
- Higher risk of resource distraction
- Less focus on core discovery programs
Evogene’s Weakness: Pre-Commercial Risk and Thin Focus
Evogene Ltd. stays weak because it is still pre-commercial, so 2025/2026 revenue depends on milestones, not steady sales. Its three-track setup and partner-led model spread cash and attention thin, while CPB concentration leaves the whole story tied to one platform. Medical cannabis adds extra regulatory drag and can distract from core R&D.
| Weakness | Data point |
|---|---|
| Pre-commercial risk | About 1 in 10 drug candidates reach approval |
| Focus risk | 3 business tracks, 1 management team |
Preview the Actual Deliverable
Evogene Ltd. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Evogene Ltd. report, and once purchased you’ll get the complete, editable version with full strengths, weaknesses, opportunities, and threats.
Opportunities
5 key crop targets
Evogene Ltd.’s five crop targets: corn, soybean, wheat, rice, and cotton sit in huge global markets, with USDA putting 2025/26 world corn output near 1.27 billion metric tons and wheat near 806 million. Even a win in one crop can matter because these are high-acreage, high-spend categories where yield and stress-tolerance traits drive repeat buying. That gives Evogene a shot at commercial upside without needing broad crop coverage first.
Microbiome therapeutics
Evogene Ltd.'s Human Health focus on microbiome therapeutics fits large unmet needs in immuno-oncology, gastrointestinal disease, and antimicrobial-resistant infections. The WHO says antimicrobial resistance caused about 1.27 million deaths in 2019, while IBD affects millions worldwide, so even small efficacy gains can matter. Microbiome-based drugs could offer differentiated, non-antibiotic treatment paths and draw strong partner interest.
Industrial castor bean
Evogene's industrial castor bean program targets a crop whose oil is about 90% ricinoleic acid, a rare profile that makes it valuable for lubricants, coatings, and chemicals. Better seed traits can lift yield and lower input costs, which can widen downstream margins and make licensing more attractive. That matters because industrial biotech buyers pay for consistent feedstock, not just acreage.
Ag biologicals expansion
Evogene’s ag biologicals work fits a market that is still scaling: global biopesticides sales were about $7 billion in 2024 and are growing at high single digits, while biological crop inputs are taking share as regulators and farmers push for lower residue and lower impact. That gives Evogene room to grow beyond chemicals into seed, spray, and soil-use products.
- Biologicals fit sustainability demand
- Market growth supports new launches
- Lower-impact inputs can widen adoption
Deeper licensing growth
Evogene Ltd. already has major validation from BASF, Corteva, and Bayer, which makes deeper licensing a realistic growth path. Those relationships can open the door to more co-development and license deals, helping Evogene test products faster and with less internal spend. For a company that still depends on external funding, more partner-funded programs can lower cash burn and reduce dilution risk.
- Existing blue-chip partners build trust.
- New licenses can speed validation.
- Partner funding can cut capital needs.
Evogene’s Crop and Biologicals Upside Could Scale Fast
Evogene Ltd. can still win from high-acreage crops: USDA puts 2025/26 corn at 1.27 billion tons and wheat at 806 million, so even one trait hit can scale fast. Its ag biologicals also ride a growing market, with global biopesticides sales near $7 billion in 2024. Partner-led deals with BASF, Corteva, and Bayer can help fund more launches.
| Opportunity | Data point |
|---|---|
| Row crops | 2025/26 corn 1.27B tons |
| Wheat | 2025/26 wheat 806M tons |
| Biologicals | 2024 sales near $7B |
| Partnerships | BASF, Corteva, Bayer |
Threats
Big competitor pressure
Evogene faces heavier hitters in biotech, ag and human health, where Bayer posted €46.6 billion in 2024 sales and Roche generated CHF 60.5 billion, dwarfing Evogene's scale. These rivals can spend far more on R&D, trials, and market launch, so they can move faster and absorb setbacks better. That makes it harder for Evogene to win deals, fund late-stage work, and protect margins.
Regulatory complexity
Evogene Ltd. faces heavy regulatory complexity because it operates in the United States, Israel, Brazil, and other markets, each with its own approval path. Its work across human health, agriculture, and cannabis-related products adds separate rules, testing steps, and review timelines. That can delay launches, raise compliance costs, and hurt revenue timing when one market stalls while others move.
Long R&D cycles
Evogene Ltd.'s computational discovery still depends on wet-lab validation and downstream development, and drug R&D often takes 10 to 15 years end to end, with success rates below 10% from preclinical to approval.
That long lag can tie up capital, push revenue recognition out, and let better-funded rivals move first.
For Evogene Ltd., any delay or failed hit can erase model value fast because early computational gains still need real-world proof.
Partner concentration risk
Evogene Ltd. depends on a small set of key partners, so any shift in one large collaborator’s strategy could hit revenue, data access, and pipeline progress fast. That also weakens pricing power in renewals and can make product timelines less stable if a partner delays, narrows, or ends a program.
For a platform business, concentration risk is not just a sales issue; it can also slow validation of new crops, traits, or microbial programs.
- Few partners, high dependency.
- Strategy changes can hit cash flow.
- Bargaining power stays limited.
- Pipeline stability can shift fast.
Cannabis market volatility
Canonic leaves Evogene Ltd exposed to a medical cannabis market that swings on regulation, pricing, and demand. In 2025, legal cannabis rules still varied sharply by country, and price cuts in mature markets kept margins thin, so returns can turn fast. That makes revenue from this line hard to forecast and raises the risk of uneven cash flow.
- Regulatory shifts can change sales overnight
- Price pressure can squeeze margins fast
- Demand swings make returns unpredictable
Evogene Faces Bigger Rivals, Longer Timelines, and Concentrated Risk
Evogene Ltd. is still outgunned by much larger biotech peers, with Bayer at €46.6B 2024 sales and Roche at CHF 60.5B, so rivals can outspend it on R&D, trials, and launches. Its multi-market regulatory load and long drug-validation cycle can delay revenue and raise costs. Partner concentration and Canonic’s cannabis exposure add cash-flow and margin risk.
| Threat | Key data |
|---|---|
| Scale gap | Bayer €46.6B; Roche CHF 60.5B |
| R&D lag | 10-15 years; <10% success |
| Partner risk | Revenue and pipeline concentration |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.